Lötstedt, Britta
Stražar, Martin http://orcid.org/0000-0003-3064-1055
Xavier, Ramnik
Regev, Aviv http://orcid.org/0000-0003-3293-3158
Vickovic, Sanja http://orcid.org/0000-0003-0985-9885
Funding for this research was provided by:
Knut och Alice Wallenbergs Stiftelse
Kjell och Märta Beijers Stiftelse
Svenska Sällskapet för Medicinsk Forskning
Royal Swedish Academy of Sciences
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (HG011014-01)
Klarman Family Foundation
Article History
Received: 21 June 2022
Accepted: 12 September 2023
First Online: 20 November 2023
Competing interests
: A.R. is a founder and equity holder of Celsius Therapeutics; is an equity holder in Immunitas Therapeutics; and, until 31 August 2020, was a scientific advisory board member of Syros Pharmaceuticals, Neogene Therapeutics, Asimov and Thermo Fisher Scientific. From 1 August 2020, A.R. is an employee of Genentech and an equity holder in Roche. S.V is an author on patents applied for by Spatial Transcriptomics AB (10x Genomics). S.V. and A.R. are co-inventors on PCT/US2020/015481, related to this work. The remaining authors declare no competing interests.